Assmann Jorn L J C, Vlachonikola Elisavet, Kolijn Pieter M, Agathangelidis Andreas, Pechlivanis Nikolaos, Papalexandri Apostolia, Stamatopoulos Kostas, Chatzidimitriou Anastasia, Langerak Anton W
Laboratory for Medical Immunology, Department of Immunology, Erasmus MC, Rotterdam, Netherlands.
Institute of Applied Biosciences, Centre for Research and Technology Hellas, Greece.
Hemasphere. 2023 Jul 17;7(8):e929. doi: 10.1097/HS9.0000000000000929. eCollection 2023 Aug.
T cell large granular lymphocyte (T-LGL) lymphoproliferations constitute a disease spectrum ranging from poly/oligo to monoclonal. Boundaries within this spectrum of proliferations are not well established. T-LGL lymphoproliferations co-occur with a wide variety of other diseases ranging from autoimmune disorders, solid tumors, hematological malignancies, post solid organ, and hematopoietic stem cell transplantation, and can therefore arise as a consequence of a wide variety of antigenic triggers. Persistence of a dominant malignant T-LGL clone is established through continuous STAT3 activation. Using next-generation sequencing, we profiled a cohort of 27 well-established patients with T-LGL lymphoproliferations, aiming to identify the subclonal architecture of the T-cell receptor beta () chain gene repertoire. Moreover, we searched for associations between gene repertoire patterns and clinical manifestations, with the ultimate objective of discriminating between T-LGL lymphoproliferations developing in different clinical contexts and/or displaying distinct clinical presentation. Altogether, our data demonstrates that the gene repertoire of patients with T-LGL lymphoproliferations is context-dependent, displaying distinct clonal architectures in different settings. Our results also highlight that there are monoclonal T-LGL cells with or without mutations that cause symptoms such as neutropenia on one end of a spectrum and reactive oligoclonal T-LGL lymphoproliferations on the other. Longitudinal analysis revealed temporal clonal dynamics and showed that T-LGL cells might arise as an epiphenomenon when co-occurring with other malignancies, possibly reactive toward tumor antigens.
T细胞大颗粒淋巴细胞(T-LGL)增殖构成了一个从多克隆/寡克隆到单克隆的疾病谱。该增殖谱内的界限尚未明确界定。T-LGL增殖与多种其他疾病同时发生,范围从自身免疫性疾病、实体瘤、血液系统恶性肿瘤、实体器官移植后以及造血干细胞移植后,因此可能由多种抗原触发因素引起。通过持续的STAT3激活建立优势恶性T-LGL克隆的持久性。我们使用下一代测序技术对27例确诊的T-LGL增殖患者进行了分析,旨在确定T细胞受体β()链基因库的亚克隆结构。此外,我们寻找基因库模式与临床表现之间的关联,最终目标是区分在不同临床背景下发生和/或表现出不同临床表现的T-LGL增殖。总之,我们的数据表明,T-LGL增殖患者的基因库取决于背景,在不同情况下显示出不同的克隆结构。我们的结果还突出表明,在一个谱系的一端存在有或没有导致中性粒细胞减少等症状的突变的单克隆T-LGL细胞,而另一端则是反应性寡克隆T-LGL增殖。纵向分析揭示了时间上的克隆动态,并表明T-LGL细胞在与其他恶性肿瘤同时发生时可能作为一种附带现象出现,可能对肿瘤抗原有反应。